Michael B. Jameson

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 364 citations · Full text

Surgical Oncology, Medicine, Melanoma +8

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Georgina V. Long, Victoria Atkinson, Jonathan Cebon et al. · The Lancet Oncology · 2017 · 246 citations · Full text

Standard-dose Pembrolizumab, Medicine, Melanoma +9

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

Jayesh Desai, Sanjeev Deva, Jong Seok Lee et al. · Journal for ImmunoTherapy of Cancer · 2020 · 145 citations · Full text

Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Susan Galbraith, Gordon Rustin, Martin A. Lodge et al. · Journal of Clinical Oncology · 2002 · 144 citations

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

Michael B. Jameson, Paul Thompson, Bruce C. Baguley et al. · British Journal of Cancer · 2003 · 139 citations · Full text